Drugs / LV20.19 CAR T cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05990465 | Feb 2025 → Jul 2026 overdue | Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +1 | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04186520 | May 2020 → Feb 2027 expected | B-cell chronic lymphocytic leukemia, central nervous system non-hodgkin lymphoma, follicular lymphoma, mantle cell lymphoma +2 | Medical College of Wisconsin | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV20.19 CAR T cells | “Seventeen patients with R/R MCL received a single dose of LV20.19 CAR T cells at 2.5 × 106 cells/kg” PMID 40163793 ↗ Mar 2025 |
| Modality | Cell therapy | “Bispecific lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T cells” PMID 35597752 ↗ May 2022 |
| Route | Intravenous | “by IV injection” NCT05990465 ↗ |